Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
LONG BEACH, Calif., and BASEL, Switzerland, June 3, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that it has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Dermatology | Drugs & Pharmacology | New Drug Applications | Psoriasis | Skin | Switzerland Health